Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti–Vascular Endothelial Growth Factor Agents
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 4 (12) , 1158-1169
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Research to Prevent Blindness
This publication has 25 references indexed in Scilit:
- Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III StudyOphthalmology, 2011
- Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III StudyOphthalmology, 2011
- The burden of disease of retinal vein occlusion: review of the literatureEye, 2011
- Baseline Predictors of Visual Acuity and Retinal Thickness Outcomes in Patients with Retinal Vein Occlusion: Standard Care versus COrticosteroid for REtinal Vein Occlusion Study Report 10Ophthalmology, 2011
- NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTSRetina, 2010
- Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One YearOphthalmology, 2009
- Accuracy of retinal thickness measurements obtained with Cirrus optical coherence tomographyBritish Journal of Ophthalmology, 2009
- SCORE Study Report 1: Baseline Associations between Central Retinal Thickness and Visual Acuity in Patients with Retinal Vein OcclusionOphthalmology, 2009
- Diurnal variation of macular oedema in CRVO: prospective studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2008
- VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrationsCurrent Eye Research, 2000